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Expanded Abstract 
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Background 
Despite previous randomised trials of early β-blocker 
therapy in the emergency treatment of myocardial infarction 
(MI), uncertainty has persisted about the value of adding it 
to current standard interventions (e.g., aspirin and 
fibrinolytic therapy), and the balance of potential benefits 
and hazards is still unclear in high-risk patients. 
Methods 
Design and setting: Prospective blinded randomized 
controlled trial in 1250 hospitals in China. 
Subjects:  45,852 patients admitted within 24 h of 
suspected acute MI onset. 93% had ST-segment elevation 
or bundle branch block, and 7% had ST-segment 
depression. 
Intervention: Subjects were randomly allocated metoprolol 
(up to 15 mg intravenous then 200 mg oral daily; n=22,929) 
or matching placebo (n=22,923). Treatment was to continue 
until discharge or up to 4 weeks in hospital (mean 15 days 
in survivors) and 89% completed it.  
Outcomes: The two pre-specified co-primary outcomes 
were: (1) composite of death, reinfarction, or cardiac arrest; 
and (2) death from any cause during the scheduled 
treatment period. Comparisons were by intention to treat, 
and used the log-rank method. This study is registered with 
ClinicalTrials.gov, number NCT 00222573. 
Results:  Neither of the co-primary outcomes was 
significantly reduced by allocation to metoprolol. For death, 
reinfarction, or cardiac arrest, 2166 (9.4%) patients 
allocated metoprolol had at least one such event compared 
with 2261 (9.9%) allocated placebo (odds ratio [OR] 0.96, 
95% CI 0.90–1.01; p=0.1). For death alone, there were 
1774 (7.7%) deaths in the metoprolol group versus 1797 
(7.8%) in the placebo group (OR 0.99, 0.92–1.05; p=0.69). 
Allocation to metoprolol was associated with fewer people 
having reinfarction (464 [2.0%] metoprolol vs. 568 [2.5%] 
placebo; OR 0.82, 0.72–0.92; p=0.001) and ventricular 
fibrillation (581 [2.5%] vs. 698 [3.0%]; OR 0.83, 0.75–0.93; 
p=0.001). Overall, these reductions were counterbalanced 
by more subjects developing cardiogenic shock (1141 
[5.0%]  vs. 885 [3.9%]; OR 1.30, 1.19–1.41; p<0.00001). 
This excess of cardiogenic shock was mainly during days 
0–1 after admission, whereas the reductions in reinfarction 
and ventricular fibrillation emerged more gradually. 
Consequently, the overall effect on death, reinfarction, 
arrest, or shock was significantly adverse during days 0–1 
and significantly beneficial thereafter. There was substantial 
net hazard in hemodynamically unstable patients, and 
moderate net benefit in those who were relatively stable 
(particularly after days 0–1). 
Conclusion 
The use of early β-blocker therapy in acute MI reduces the 
risks of reinfarction and ventricular fibrillation, but increases 
the risk of cardiogenic shock, especially during the first day 
or so after admission. Consequently, it might generally be 
prudent to consider starting β-blocker therapy in hospital 
only when the hemodynamic condition after MI has 
stabilized. 
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Commentary 
β-blockers are a fundamental therapeutic tool in the 
management of many conditions seen in ICU patients, 
including hypertension, aortic dissection, and various 
arrhythmias/tachycardias. Based on American Heart 
Association emergency cardiac care guidelines [2], both IV 
and oral β-blockers are often utilized for initial management 
of acute MI. The potential benefits of early therapy are well 
understood, and include reduced risks for ventricular 
fibrillation and reinfarction. Long-term oral therapy is 
associated with a number of benefits including secondary 
prevention, reduced mortality, and improved left ventricular 
function. 
The evidence base for early β-blocker use was generated 
mostly in the pre-thrombolytic era and use has been 
perpetuated by practice guidelines [2,3]. The current study, 
COMMIT/CCS-2 [1], appropriately re-addressed the 
question of whether β-blocker use is still appropriate under 
contemporary conditions, which include access to 
thrombolytics, rapid percutaneous coronary intervention, 
emergent cardiac bypass, adjuncts such as intra-aortic 
balloon pumps, and well-established medical therapies, 
such as aspirin and angiotensin converting enzyme 
inhibitors.  
In the present study, 45,852 subjects were randomized to IV 
followed by oral metoprolol or matching placebo within 24 h 
of onset of a suspected acute MI. The study included a mix 
of low risk, moderate risk, and high risk patients, but 
excluded those undergoing percutaneous coronary 
interventions. The groups were well-balanced at baseline. 
Compliance and follow-up were excellent.  
Surprisingly, there were no differences between groups for 
the co-primary outcomes of: (1) composite of death, 
reinfarction, or cardiac arrest; and (2) death from any cause 
during the scheduled treatment period. The finding of no 
mortality benefit associated with early metoprolol treatment 
was driven by two opposing effects: increased risk of 
cardiogenic shock in days 0-1 with an offsetting reduction in 
ventricular fibrillation and reinfarction that occurred later in 
the hospital stay. These biologically plausible findings can 
at least partially be explained by the inclusion of high risk 
subjects, such as those presenting with pulmonary 
congestion. However, even among patients with 
hypertension, tachycardia, or Killip class 1 status 
(individuals with no clinical signs of heart failure), there was 
a greater risk of cardiogenic shock with metoprolol, 
suggesting that even these individuals do not universally 
tolerate early β-blockade.  
A few limitations of this study warrant consideration. It is 
common practice to use oral doses of metoprolol that are 
much less than the 50 mg every 6h that was employed in 
COMMIT/CCS-2. Furthermore, the initial IV doses were 
given at relatively frequent intervals, every 2-3 minutes over 
a 2-3 minute period. Customizing the approach, either by 
waiting longer between IV doses or by using a lower 
subsequent oral dose, might help limit progression to drug-
associated cardiogenic shock. Because this study focused 
on subjects presenting with acute MI, care providers should 
use caution in extrapolating these results to the 
management of acute MI occurring in patients already 
admitted to an ICU for other reasons. Many of these 
patients (surgical or otherwise) have contraindications to 
therapies, such as anticoagulation or coronary intervention, 
and  β-blockers may therefore take on a relatively more 
important role.  
Recommendation 
Early  β-blocker use in the setting of suspected acute MI 
deserves careful consideration of the relative risks and 
benefits. Cardiogenic shock appears to be a significant risk, 
with the potential to outweigh later benefits. These drugs 
should only be used with frequent hemodynamic 
assessment and only once the hemodynamic condition after 
MI has stabilized. 
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